Discovery, structure - Activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3520-3535

  Pei, Zhonghua ^a   Li, Xiaofeng ^a   Longenecker, Kenton ^a   Von Geldern, Thomas W ^a   Wiedeman, Paul E ^a   Lubben, Thomas H ^a   Zinker, Bradley A ^a   Stewart, Kent ^a   Ballaron, Stephen J ^a   Stashko, Michael A ^a   Mika, Amanda K ^a   Beno, David W A ^a   Long, Michelle ^a   Wells, Heidi ^a   Kempf Grote, Anita J ^a   Madar, David J ^a   McDermott, Todd S ^a   Bhagavatula, Lakshmi ^a   Fickes, Michael G ^a   Pireh, Daisy ^a   Solomon, Larry R ^a   Lake, Marc R ^a   Edalji, Rohinton ^a   Fry, Elizabeth H ^a   Sham, Hing L ^a   Trevillyan, James M ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANOPYRROLIDINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRROLIDINE DERIVATIVE; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; FEMALE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-OBESITY AGENTS; ANTIGENS, CD26; BLOOD GLUCOSE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG STABILITY; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; NITRILES; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745148202     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051283e     Document Type: Article

References (59)

1. For reviews, see: (a) Holst, J. J. On the Physiology of GIP and GLP-1. Horm. Metab. Res. 2004, 36, 747-754.
2. (b) Gautier, J. F.; Fetita, S.; Sobngwi, E.; Salaün-Martin, C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005, 31, 233-242.
3. (a) Mojsov, S.; Weir, G. C.; Habener, J. F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79, 616-619.
4. (b) Kreymann, B.; Ghatei, M. A.; Williams, G.; Bloom, S. R. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987, 2, 1300-1304.
5. (c) Orskov, C.; Hoist, J. J.; Nielsen, O. V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123, 2009-2013.
6. Nauck, M. A.; Heimesaat, M. M.; Behle, K.; Holst, J. J.; Nauck, M. S.; Ritzel, R.; Hufner, M.; Schmiegel, W. H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol Metab. 2002, 87, 1239-1246.
7. (a) Wettergren, A.; Schjoldager, B.; Mortensen, P. E.; Myhre, J.; Christiansen, J.; Hoist, J. J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38, 665-673.
8. (b) Nauck, M. A.; Niedereichholz, U.; Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel, R.; Schmiegel, W. H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Phvsiol. 1997, 273, E981-E988.
9. Meier, J. J. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Practice Res. Clin. Endocrinol. Metab. 2004, 18, 587-606.
10. (a) Mentlein, R.; Ballwitz, B.; Schmidt, W. E. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagonlike peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214, 829-835.
11. (b) Kieffer, T. J.; McIntosh, C. H. S.; Pederson, T. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136, 3585-3596.
12. (c) for a review, see: Deacon, C. F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 2004, 36, 761-765.
13. Ahrén, B.; Schmitz, O. GLP-1 Receptor agonist and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 2004, 36, 867-876.
14. For two excellent reviews, see: (a) Gorrell, M. D.; Gysbers, V.; McCaughan, G. W. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 2001, 54, 249-264.
15. (b) Meester, I. De; Durinx, C.; Proost, P.; Scharpe. S.; Lambier, A.-M. In Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology: Langner, J., Ansorge, S.; Ed.: Kluwer Academic/Plenum Publisher: New York, 2002; pp 223-257.
16. (a) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A. M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secrection and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000. 97, 6874-6879.
17. (b) Conarello, S. L.; Li, Z.; Ronan, J.; Roy, R. S.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6825-6830.
18. Nagakura, T.; Vasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fisher rats. Biochem. Biophys. Res. Commun. 2001, 284, 501-506.
19. (a) Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-875.
20. (b) Ahren, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
21. (c) Ahrén, B.; Landing-Olsson, L.; Jansson, P.-A.; Sevensson, M.; Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
22. (d) Ahrén, B.; Pacini, Giovanni; Foley, James E.; Schweizer, A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28, 1936-1940.
23. Farilla, L.; Hui, H.; Bertolotto, C.; Kang, E.; Bulotta, A.; Di Mario, U.; Perfetti, R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143, 4397-4408.
24. Reimer, M. K.; Holst, J. J.; Ahren, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 2002, 146, 717-727.
25. Pospisilik, A.; Martin, J.; Doty, T.; Ehses, J. A.; Pamir, N.; Lynn, F. C.; Piteau, S.; Demuth, H.-U.; McIntosh, C. H. S.; Pederson, R. A. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52, 741-750.
26. (a) Schön, E., Born, I., Demuth, H.-U., Faust, J., Neubert, K., Steinmetzer, T., Barth, A., Ansorge, S. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe-Seyler 1991, 372, 305-311.
27. (b) Pederson, R. A.; White, H. A.; Schienzig, D.; Pauly, R. P.; McIntosh, C. H. S.; Demuth, H.-U. Improved glucose tolerance in zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998, 47, 1253.
28. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D.; Russell, M. E.; Weldon, S. C. Hughes, T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(5)-pyrrolidine- carbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2002, 45, 2362-2365.
29. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46, 2774-2789.
30. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Sinha Roy, R.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase iv inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 141-151.
31. Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 5025-5037.
32. (a) Sorbera, L. A.; Revel, L.; Castaner, J. P32/98: Antidiabetic dipeptidyl-peptidase IV inhibitor. Drugs Future 2001, 26, 859-864.
33. (b) Deacon, C. F. MK-0431 Merck. Curr. Opin. Invest. Drugs 2005, 6, 419-426.
34. Ezquerra, J.; Pedregal, C.; Rubio, A.; Valenciano, J.; Navio, J. L. C.; Alvarez-Builla, J.; Vaquera, J. J. General method for the synthesis of 5-arylpyrrole-2-carboxylic acids. Tetrahedron Lett. 1993, 34, 6317-6320.
35. Manfre, F.; Kern, J.-M.; Biellmann, J.-F. Synthesis of prolyline analogues as potential mechanism-based inhibitors of proline dehydrogenase: 4-Methylene-L-, (E)- and (Z)-4-(fluoromethylene)-L, cis- and trans-5-ethynyl-(±)-, and cis- and trans-5-vinyl-1-proline. J. Org. Chem. 1992, 57, 2060-2065.
36. 4 revisited: Oxidation of aldehydes to carboxylic acids in the tertbutyl alcohol-aqueous NaH2PU4 system. Tetrahedron Lett. 1986, 27, 4537-4540.
37. (a) Tsunoda, T.; Ozaki, F.; Ho, S. Novel reactivity of stabilized methylenetributylphosphorane: A new Mitsunobu reagent. Tetrahedron Lett. 1994, 35, 5081-5082.
38. (b) For a review, see: Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
39. Zhang, R.; Qian, X.; Zhou, W. A Facile synthesis of 3-chloro-4-(2′, 2′,2′-trifluoroethoxy)benzonitrile. Org. Prep. Proc. Intl. 1999, 31, 110-111.
40. Ashworth, D.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 2-Cyanopyrrolidines as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, 1163-1166.
41. (a) Zhao, G.; Taunk, P. C.; Magnin, D. R.; Simpkins, L. M.; Robl, J. A.; Wang, A.; Robertson, J. G.; Marcinkeviciene, J.; Sitkoff, D. F.; Parker, R. A.; Kirby, M. S.; Hamann, L. G. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3992-3995.
42. (b) Sakashita, H.; Kitajima, H.; Nakamura, M.; Akahoshi, F. Hayashi, Y. 1-((S)-γ-Substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2441-2445.
43. For an example of discussion of chemical stability, see Magnin, D. R.; Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L. M.; Taunk, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.; Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han, S.-P.; Parker, R. A.; Hamann, L. G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: Interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of a-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem. 2004, 47, 2587-2598.
44. Morrison, J.; Walsh, C. T. In Advances in Enzymology; Meister, A. Ed.; John Wiley & Sons: New York, 1988; Vol. 61, pp 201-301.
45. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C.-C; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, Z.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54, 2988-2994.
46. Leiting, B.; Pryor, K. D.; Wu, J. K.; Marsilio, F.; Patel, R. A.; Craik, C. S.; Ellman, J. A.; Cummings, R. T.; Thornberry, N. A. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. 2003, 371, 525-532.
47. Abbott, C. A.; Yu, D. M. T.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000, 267, 6140-6150.
48. Ajami, K.; Abbott, C. A.; McCaughan, G. W.; Gorrell, M. D. Dipeptidyl poptidase 9 has two forms, a broad tissue distrubution, cytoplasmic localization and DPP-like peptidase activity. Biochem Biophys. Acta 2004, 1679, 18-28.
49. Rosenblum, J. S.; Kozarich, J. W. Prolyl peptidases: A serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 2003, 7, 496-504.
50. Scanlan, M. J.; Raj, B. K. M.; Calvo, B.; Garin-Chesa, P.; Sanz-Moncasi, M. P.; Healey, J. H.; Old, L. J. Rettig, W. J. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in a stromal fibroblasts of epithelial cancers. Proc. Natl Acad. Sci. U.S.A. 1994, 91, 5657-5661.
51. Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10, 19-25.
52. Refined crystallographic coordinates for the structures of DPPIV complexed with 21ac, 21ag and 21b have been deposited in Protein Data Bank (www.rcsb.org) with entry codes 2G5P, 2G5T, and 2G63, respectively.
53. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.-U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068.
54. Morrison, J. F.; Stone, S. R. Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors. Comments Mol. Cell Biophys. 1985, 2, 347-368.
55. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
56. (a) Vagin, A.; Teplyakov, A. MOLREP: An automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
57. (b) CCP4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. Sect. D 1994, D50, 760-763.
58. (a) St-Denis, Y.; Augelli-Szafran, C. E.; Bachand, B.; Berryman, K. A.; DiMaio, J.; Doherty, A. M.; Edmunds, J. J.; Leblond, L.; Levesque, S.; Narasimhan, L. S.; Penvose-Yi, J. R.; Rubin, J. R.; Tarazi, M.; Winocour, P. D.; Siddiqui, M. A. Potent bicyclic lactam inhibitors of thrombin: Parti: P3 modifications. Bioorg. Med. Chem. Lett. 1998, 8, 3193-3198.
59. (b) Jain, R. Convenient N-Protection of L-Pyroglutamic Acid Esters. Org. Prep. Proc. Intl. 2001, 33, 405-409.